These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8461270)

  • 21. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients.
    Nayak RK; Doose DR; Nair NP
    J Clin Pharmacol; 1987 Feb; 27(2):144-50. PubMed ID: 3680566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Haloperidol decanoate. Results of an open-ended multicentric study in chronic psychotic states].
    Lemperiere T; Ropert R; Leger JM; Alexandre JY; Clerc G; Darondel A; Delaunay J; Delteil P; Malauzat D; Raynaud J
    Encephale; 1984; 10(5):217-22. PubMed ID: 6519017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate.
    Sassa T; Suhara T; Ikehira H; Obata T; Girard F; Tanada S; Okubo Y
    Psychiatry Clin Neurosci; 2002 Dec; 56(6):637-42. PubMed ID: 12485307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do enzyme inducers modify haloperidol decanoate rate of release?
    Pupeschi G; Agenet C; Levron JC; Barges-Bertocchio MH
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Dec; 18(8):1323-32. PubMed ID: 7863019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-term therapy of chronic schizophrenic patients with haloperidol decanoate].
    Roncoroni D
    Psychiatr Prax; 1984 Mar; 11(2):56-8. PubMed ID: 6144121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
    Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
    Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of haloperidol decanoate on plasma homovanillic acid in chronic schizophrenic patients.
    Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Lane HY; Jann MW
    Biol Psychiatry; 1993 Apr; 33(7):557-9. PubMed ID: 8513043
    [No Abstract]   [Full Text] [Related]  

  • 28. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
    Nyberg S; Farde L; Halldin C
    Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics.
    Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YF; Jann MW
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):105-12. PubMed ID: 8416597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
    McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
    Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Haloperidol decanoate: results of a 6-month open trial in paranoid schizophrenia].
    Pérez C; Stier Rosner SE
    Acta Psiquiatr Psicol Am Lat; 1989; 35(3-4):111-5. PubMed ID: 2576990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study.
    Chang WH; Lin SK; Jann MW
    J Clin Psychopharmacol; 1991 Apr; 11(2):99-105. PubMed ID: 2056148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clozapine in tardive Tourette syndrome.
    Jaffe E; Trémeau F; Sharif Z; Reider R
    Biol Psychiatry; 1995 Aug; 38(3):196-7. PubMed ID: 7578666
    [No Abstract]   [Full Text] [Related]  

  • 35. Low plasma reduced haloperidol/haloperidol ratios in Chinese patients.
    Chang WH; Chen TY; Lee CF; Hu WH; Yeh EK
    Biol Psychiatry; 1987 Nov; 22(11):1406-8. PubMed ID: 3663790
    [No Abstract]   [Full Text] [Related]  

  • 36. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects.
    Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S
    J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study.
    Wistedt B; Koskinen T; Thelander S; Nerdrum T; Pedersen V; Mølbjerg C
    Acta Psychiatr Scand; 1991 Jul; 84(1):14-21. PubMed ID: 1681680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid.
    Aymard N; Viala A; Stein I; Caroli F
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Nov; 19(7):1119-35. PubMed ID: 8787036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics of the depot antipsychotics.
    Jann MW; Ereshefsky L; Saklad SR
    Clin Pharmacokinet; 1985; 10(4):315-33. PubMed ID: 2864156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
    Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
    J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.